Kenichi Akiyama^1,2, Makoto Kuro-O², Yutaka Miura², Hiroshi Kawaguchi³, Kosaku Nitta¹

Show more
¹ Department of Nephrology, Tokyo Women’s Medical University, Tokyo, Japan.
² Division of Anti-Aging Medicine, Center for Molecular Medicine, Jichi Medical University, Tochigi, Japan.
³ Department of Nephrology, Jyoban Hospital, Fukushima, Japan.
Show less

Abstract: Background: Arterial calcification is a predictive marker in patient on hemodialysis (HD), but the relationship between arterial calcification and calciprotein particles (CPPs) is unclear. Methods: We examined the effects of ferric citrate hydrate (JTT-751) on CPP level and evaluated changes in aortic arch calcification (AoAC) grade in patients on maintenance HD (MHD). In total, 70 MHD patients were enrolled in the study and followed for 24 months. We measured serum CPP levels and fibroblast growth factor 23 (FGF 23) among propensity score-matched MHD patients. One group (n = 35) was treated with CaCO₃ and the other (n = 35) was treated with ferric citrate hydrate (JTT-751). AoAC was assessed on chest-X rays. Eligible patients continued the same treatment. Results: All 70 patients completed the study. Serum CPP levels reduced in the JTT-751 group, but were not significantly different in the CaCO₃ group. Among patients whose baseline AoAC score (AoACS) was ≤ 4 (median), median AoACS increased from 0 (0 - 3) to 3 (2 - 4) (p < 0.05) and Δ% AoACS was 2 (0% - 4%) in the JTT-751 group. In the CaCO₃ group, median AoACS increased from 2 (0 - 2) to 3 (0 - 4) (p < 0.05) and Δ% AoACS was 1 (0% - 3%). Conclusion: These results indicate that the administration of JTT-751 decreased serum CPP levels but did not inhibit AoAC progression in patients on MHD.

Keywords: Hemodialysis, Ferric Citrate Hydrate, Calciprotein Particles, Vascular Calcification

Cite this paper: Akiyama, K. , Kuro-O, M. , Miura, Y. , Kawaguchi, H. and Nitta, K. (2020) Effects of Ferric Citrate Hydrate on Calciprotein Particle Levels and Aortic Arch Calcification Progression in Patients on Maintenance Hemodialysis: A Comparison with Calcium Carbonate. International Journal of Clinical Medicine, 11, 1-14. doi: 10.4236/ijcm.2020.111001.

References

[1]   Hruska, K.A. and Mathew, S. (2011) The Roles of the Skeleton and Phosphorus in the CKD Mineral Bone Disorder. Advances in Chronic Kidney Disease, 18, 98-104.
https://doi.org/10.1053/j.ackd.2011.01.001

[2]   Taniguchi, M., Fukagawa, M., Fujii, N., Hamano, T., Shoji, T., Yokoyama, K., et al. (2013) Serum Phosphate and Calcium Should Be Primarily and Consistently Controlled in Prevalent Hemodialysis Patients. Therapeutic Apheresis and Dialysis, 17, 221-228.
https://doi.org/10.1111/1744-9987.12030

[3]   Chiu, Y.W., Teitelbaum, I., Misra, M., de Leon, E.M., Adzize, T. and Mehrotra, R. (2009) Pill Burden, Adherence, Hyperphosphatemia, and Quality of Life in Maintenance Dialysis Patients. Clinical Journal of American Society of Nephrology, 4, 1089-1096.
https://doi.org/10.2215/CJN.00290109

[4]   Isakova, T., Gutierrez, O.M., Chang, Y., Shah, A., Tamez, H., Smith, K., et al. (2009) Phosphorus Binders and Survival on Hemodialysis. Journal of American Society of Nephrology, 20, 388-396.
https://doi.org/10.1681/ASN.2008060609

[5]   Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney International Supplement, 113, S1-S130.

[6]   Price, P.A., Thomas, G.R., Pardini, A.W., Fiqueira, W.F., Capulo, J.M. and Williamson, M.K. (2002) Discovery of a High Molecular Weight Complex of Calcium, Phosphate, Fetuin, and Matrix Gamma-Carboxyglutamic Acid Protein in the Serum of Etidronate-Treated Rats. Journal of Biological Chemistry, 277, 3926-3934.
https://doi.org/10.1074/jbc.M106366200

[7]   Hamano, T., Matsui, I., Mikami, S., Tomida, K., Fujii, N., Imai, E., et al. (2010) Fetuin-Mineral Complex Reflects Extraosseous Calcification Stress in CKD. Journal of American Society of Nephrology, 21, 1998-2007.
https://doi.org/10.1681/ASN.2009090944

[8]   Smith, E.R., Ford, M.L., Tomlinson, L.A., Rajkumar, C., McMahon, L.P. and Holt, S.G. (2012) Phosphorylated Fetuin A-Containing Calciprotein Particles Are Associated with Aortic Stiffness and a Procalcific Milieu in Patients with Pre-Dialysis CKD. Nephrology Dialysis Transplantation, 27, 1957-1966.
https://doi.org/10.1093/ndt/gfr609

[9]   Miura, Y., Iwazu, Y., Shiizaki, K., Akimoto, T., Kotani, K., Kurabayashi, M., et al. (2018) Identification of Plasma Calciprotein Particles with Distinct Physical Properties in Patients with Chronic Kidney Disease. Scientific Reports, 8, Article No. 1256.
https://doi.org/10.1038/s41598-018-19677-4

[10]   Yang, W.C., Yang, C.S., Hou, C.C., Wu, T.H., Young, E.W. and Hsu, C.H. (2002) An Open-Label, Crossover Study of a New Phosphate-Binding Agent in Haemodialysis Patients: Ferric Citrate. Nephrology Dialysis Transplantation, 17, 265-270.
https://doi.org/10.1093/ndt/17.2.265

[11]   Yokoyama, K., Hirakata, H., Akiba, T., Sawada, K. and Kumagai, Y. (2012) Effect of Oral JTT-751 (Ferric Citrate) on Hyperphosphatemia in Hemodialysis Patients: Results of a Randomized, Double-Blind, Placebo-Control Trial. American Journal of Nephrology, 36, 478-487.
https://doi.org/10.1159/000344008

[12]   Umanath, K., Sika, M., Niecestro, R., Connelly, C., Schulman, G., Koury, M.J., et al. (2013) Rationale and Study Design of a Three-Period, 58-Week Trial of Ferric Citrate as a Phosphate Binder in Patients with ESRD on Dialysis. Hemodialysis International, 17, 67-74.
https://doi.org/10.1111/j.1542-4758.2012.00711.x

[13]   Ogawa, T., Ishida, H., Matsuda, N., Fujiu, A., Matsuda, A., Ito, K., et al. (2009) Simple Evaluation of Aortic Arch Calcification by Chest Radiography in Hemodialysis Patients. Hemodialysis International, 13, 301-306.
https://doi.org/10.1111/j.1542-4758.2009.00366.x

[14]   Akiyama, K., Mochizuki, T., Kataoka, H., Tsuchiya, K. and Nitta, K. (2017) Fibroblast Growth Factor 23 and Soluble Klotho in Patients with Autosomal Dominant Polycystic Kidney Disease. Nephrology (Carlton), 22, 848-853.
https://doi.org/10.1111/nep.12862

[15]   Daugirdas, J.T. (1993) Second Generation Logarithmic Estimates of Single-Pool Variable Volume Kt/V: An Analysis of Error. Journal of American Society of Nephrology, 4, 1205-1213.

[16]   Shinzato, T., Nakai, S., Fujita, Y., Takai, I., Morita, H., Nakane, K., et al. (1994) Determination of Kt/V and Protein Catabolic Rate Using Pre- and Postdialysis Blood Urea Nitrogen Concentrations. Nephron, 67, 280-290.
https://doi.org/10.1159/000187980

[17]   Akiyama, K., Kimura, T. and Shiizaki, K. (2018) Biological and Clinical Effects of Calciprotein Particles on Chronic Kidney Disease-Mineral and Bone Disorder. International Journal of Endocrinology, 2018, Article ID: 5282389.
https://doi.org/10.1155/2018/5282389

[18]   Sinsakul, M., Sika, M., Koury, M., Shapiro, W., Greene, T., Dwyer, J., et al. (2012) The Safety and Tolerability of Ferric Citrate as a Phosphate Binder in Dialysis Patients. Nephron Clinical Practice, 121, c25-c29.
https://doi.org/10.1159/000341922

[19]   Dwyer, J.P., Sika, M., Schulman, G., Chang, I.J., Anger, M., Smith, M., et al. (2013) Dose-Response and Efficacy of Ferric Citrate to Treat Hyperphosphatemia in Hemodialysis Patients: A Short-Term Randomized Trial. American Journal of Kidney Disease, 61, 759-766.
https://doi.org/10.1053/j.ajkd.2012.11.041

[20]   Iida, A., Kemmochi, Y., Kakimoto, K., Tanimoto, M., Mimura, T., Shinozaki, Y., et al. (2013) Ferric Citrate, a New Phosphate Binder, Prevents the Complications of Secondary Hyperparathyroidism and Vascular Calcification. American Journal of Nephrology, 37, 346-358.
https://doi.org/10.1159/000348805

[21]   Pasch, A., Fareses, S., Graber, S., Wald, J., Richtering, W., Floege, J., et al. (2012) Nanoparticle-Based Test Measures Overall Propensity for Calcification in Serum. Journal of American Society of Nephrology, 23, 1744-1752.
https://doi.org/10.1681/ASN.2012030240

[22]   Aghagolzadeh, P., Bachtler, M., Bijamia, R., Jackson, C., Smith, E.R., Odermatt, A., et al. (2016) Calcification of Vascular Smooth Muscle Cells Is Induced by Secondary Calciprotein Particles and Enhanced by Tumor Necrosis Factor-α. Atherosclerosis, 251, 404-414.
https://doi.org/10.1016/j.atherosclerosis.2016.05.044

[23]   Matsui, I., Hamano, T., Mikami, S., Fujii, N., Takabatake, Y., Nagasawa, Y., et al. (2009) Fully Phosphorylated Fetuin-A Forms a Mineral Complex in the Serum of Rats with Adenine-Induced Renal Failure. Kidney International, 75, 915-928.
https://doi.org/10.1038/ki.2008.700

[24]   Herrmann, M., Schafer, C., Heiss, A., Graber, S., Kinkeldey, A., Buscher, A., et al. (2012) Clearance of Fetuin-A-Containing Calciprotein Particles Is Mediated by Scavenger Receptor-A. Circulation Research, 111, 575-584.
https://doi.org/10.1161/CIRCRESAHA.111.261479

[25]   Nitta, K., Hanafusa, N., Okazaki, M., Komatsu, M., Kawaguchi, H. and Tsuchiya, K. (2018) Association between Risk Factors Including Bone-Derived Biomarkers and Aortic Arch Calcification in Maintenance Hemodialysis Patients. Kidney Blood Pressure Research, 43, 1554-1562.
https://doi.org/10.1159/000494441

[26]   Ogawa, T. and Nitta, K. (2018) Pathogenesis and Management of Vascular Calcification in Patients with End-Stage Renal Disease. Contribution to Nephrology, 196, 71-77.
https://doi.org/10.1159/000485702

[27]   Qunibi, W.Y. (2007) Cardiovascular Calcification in Nondialyzed Patients with Chronic Kidney Disease. Seminar in Dialysis, 20, 134-138.
https://doi.org/10.1111/j.1525-139X.2007.00260.x

[28]   Lewis, J.B., Sika, M., Koury, M.J., Chuang, P., Schulman, G., Smith, M.T., et al. (2015) Ferric Citrate Controls Phosphorus and Delivers Iron in Patients on Dialysis. Journal of the American Society of Nephrology, 26, 493-503.
https://doi.org/10.1681/ASN.2014020212

[29]   Umanath, K., Jalal, D.I., Greco, B.A., Umeukeje, E.M., Reisin, E., Manley, J., et al. (2015) Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. Journal of American Society of Nephrology, 26, 2578-2587.
https://doi.org/10.1681/ASN.2014080842

[30]   Yokoyama, K., Akiba, T., Fukagawa, M., Nakayama, M., Sawada, K., Kumagai, Y., et al. (2014) A Randomized Trial of JTT-751 versus Sevelamer Hydrochloride in Patients on Hemodialysis. Nephrology Dialysis Transplantation, 29, 478-487.
https://doi.org/10.1093/ndt/gft483

[31]   Lee, C.T., Wu, I.W., Chiang, S.S., Peng, Y.S., Shu, K.H., Wu, M.J., et al. (2015) Effect of Oral Ferric Citrate on Serum Phosphorus in Hemodialysis Patients: Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Journal of Nephrology, 28, 105-113.
https://doi.org/10.1007/s40620-014-0108-6

[32]   Ketteler, M., Liangos, O. and Biggar, P.H. (2016) Treating Hyperphosphatemia-Current and Advancing Drugs. Expert Opinion on Pharmacotherapy, 17, 1873-1879.
https://doi.org/10.1080/14656566.2016.1220538